Laddar...
Evolution of anti-CD20 monoclonal antibody therapeutics in oncology
Approval of an anti-CD20 chimeric monoclonal antibody, rituximab, has revolutionized cancer treatment and also validated CD20 targeting for providing benefit and improvement of overall response rate in B cell malignancies. Although many patients have benefited from the treatment of rituximab, there...
Sparad:
| Huvudupphovsmän: | , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Landes Bioscience
2010
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2828574/ https://ncbi.nlm.nih.gov/pubmed/20081379 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|